Spruce Biosciences, Inc. (Nasdaq: SPRB), a South San Francisco-based biopharmaceutical company developing therapies for neurological disorders, will present additional natural history analyses of Sanfilippo syndrome type B, also known as mucopolysaccharidosis type IIIB (MPS IIIB), at the 55th Child Neurology Society Annual Meeting in Montreal, Canada. Announced on October 8, 2026, the presentation will examine cognitive, motor, communication and adaptive functioning in children with severe MPS IIIB, providing additional disease progression context as the company prepares a United States Food and Drug Administration submission for tralesinidase alfa enzyme replacement therapy.
The presentation is scheduled for October 15 and will draw on Study 250-902, registered as NCT03227042, a prospective, multicentre, multinational, noninterventional study of children affected by MPS IIIB. The analyses are intended to characterize how neurological and developmental abilities change as the disease progresses, an important consideration when evaluating potential treatments for a rare disorder associated with progressive loss of childhood skills. Spruce has identified Professor Ilyas Okur of Gazi University in Türkiye as the presenter of the study’s findings.
The announcement is relevant to Spruce’s regulatory strategy because its investigational treatment, tralesinidase alfa enzyme replacement therapy (TA-ERT), is being developed through a potential accelerated approval pathway based on changes in cerebrospinal fluid heparan sulfate non-reducing ends. Earlier company-reported analyses have associated TA-ERT treatment with substantial biomarker reductions and preservation of cognitive and functional abilities relative to untreated natural history participants. However, the forthcoming conference presentation has not yet disclosed its new numerical results, meaning its incremental contribution to the treatment’s evidence package cannot be assessed before the data are presented.
Spruce expects to submit a biologics license application for TA-ERT during the fourth quarter of 2026 and plans to initiate a separate confirmatory study examining cognitive outcomes in young children with severe MPS IIIB. The company is pursuing this strategy in a disease for which no FDA-approved treatment currently exists, creating an urgent therapeutic need alongside significant clinical and regulatory uncertainty. The value of the new natural history analyses will depend on whether they improve understanding of untreated disease progression and support credible interpretation of the company’s interventional results.
Why is the MPS IIIB natural history study important for understanding childhood neurological decline?
Sanfilippo syndrome type B is an inherited lysosomal storage disorder caused by deficiency of the enzyme alpha-N-acetylglucosaminidase, commonly abbreviated as NAGLU. The enzyme is required to break down heparan sulfate, a complex molecule involved in normal cellular processes. When NAGLU activity is deficient, heparan sulfate accumulates within cells, contributing to progressive neurological damage and additional systemic manifestations.
Children with severe MPS IIIB may initially experience developmental delays, behavioural difficulties and speech impairment before progressively losing previously acquired abilities. As the disease advances, cognitive functioning, communication, motor coordination and everyday independence can deteriorate substantially. The severity and timing of these changes vary between individuals, complicating the assessment of experimental treatments when patient populations are extremely small.
Natural history research helps establish what typically happens in the absence of disease-modifying treatment. In disorders such as MPS IIIB, these observations can provide essential information about the expected trajectory of neurological function, the age at which deterioration becomes measurable and the variability between patients. Such evidence is particularly important when conventional large randomized trials are difficult to conduct because of disease rarity and the burden of invasive procedures.
Study 250-902 was designed to follow patients over time rather than administer an investigational medicine. Earlier published work incorporating this study and a companion natural history investigation examined 65 children in total, including 43 enrolled in Study 250-902 at the time of the analysis. The new October 2026 presentation specifically concerns further characterization of severe, non-attenuated MPS IIIB, although Spruce has not disclosed the number of participants included in the forthcoming analyses.
The distinction between severe and attenuated disease matters because individuals with attenuated forms may retain neurological abilities for longer periods. Combining patients with substantially different disease trajectories can obscure the interpretation of changes in cognition and functioning. A more clearly characterized severe-disease population may therefore provide a stronger basis for comparing outcomes across treated and untreated groups, provided important baseline differences are addressed.
What does previous MPS IIIB research reveal about cognitive decline and the loss of developmental abilities?
A peer-reviewed study published in The Journal of Pediatrics in 2022 examined longitudinal natural history findings from Studies 250-901 and 250-902. Investigators reported that most children with non-attenuated MPS IIIB reached their highest cognitive and adaptive behaviour age-equivalent scores between three and six years of age. The subsequent course involved progressive deterioration in developmental functioning, with substantial impairment generally becoming evident during childhood.
The researchers found that cognitive and adaptive developmental quotients declined along broadly predictable trajectories in patients with severe disease. Developmental quotient measurements relate assessed developmental age to chronological age, helping researchers describe the widening difference between an affected child’s developmental capabilities and those expected for their age. In the published analysis, children with non-attenuated disease reached developmental quotients below approximately 25 by eight years of age on average, although some reached that level later.
The study also reported evidence of structural neurological deterioration. Among participants assessed with brain imaging, average brain volume declined by approximately 26 millilitres over 48 weeks, corresponding to a reduction of 2.7%. The reported loss was attributable to cortical grey matter reduction, which averaged approximately 32 millilitres, or 6.5%, over the same period.
These findings help establish the extent of neurological disease progression, but they are historical observations rather than results from the October 2026 presentation. The forthcoming analyses may provide additional detail about specific functional domains, including communication and motor abilities, but their numerical findings remain undisclosed. It would therefore be premature to describe the new poster as demonstrating a particular rate of deterioration or validating a specific treatment effect.
The earlier study also highlighted limitations associated with cognitive assessment in advanced neurological disease. Developmental quotients can become less informative when patients have already reached very low levels of functioning, while age-equivalent and raw-score measures may respond differently to changes in younger children. Researchers evaluating experimental therapies must account for these measurement characteristics to avoid interpreting a stable score as evidence of preserved neurological function when the instrument has limited sensitivity.
How could natural history findings support Spruce Biosciences’ accelerated approval strategy for TA-ERT?
Spruce is developing TA-ERT through an accelerated approval strategy focused on reducing cerebrospinal fluid heparan sulfate non-reducing ends, referred to as CSF HS-NRE. This biomarker reflects the accumulation of disease-related substrate associated with NAGLU deficiency and provides a measurable indication of the treatment’s biochemical activity. The company believes that substantial and sustained reductions could be reasonably likely to predict clinical benefit in patients with MPS IIIB.
The proposed regulatory approach requires a distinction between biological target engagement and demonstrated clinical improvement. A reduction in CSF HS-NRE can indicate that treatment is affecting the underlying biochemical abnormality, but it does not independently establish preservation of cognition, motor function or survival. Accelerated approval permits the FDA to consider surrogate endpoints reasonably likely to predict clinical benefit in qualifying circumstances, while requiring further evidence to verify the anticipated benefit.
Natural history information becomes valuable because it can place treated patients’ developmental trajectories in context. If untreated children with comparable disease characteristics typically lose cognitive or functional abilities over a predictable period, sustained preservation among treated children may provide supportive clinical evidence. However, comparisons between separate patient groups remain vulnerable to differences in age, baseline disease severity, genetic variants, supportive care and assessment methods.
Spruce reported in February 2026 that long-term TA-ERT treatment was associated with stabilization of cognitive and non-cognitive outcomes relative to natural history patients. The company also described preservation of receptive and expressive communication, fine and gross motor abilities and cortical grey matter volume in its treated population. These findings are encouraging, but the comparisons do not carry the same methodological protections as a randomized, concurrently controlled study.
The FDA’s regulatory assessment will therefore need to consider the complete evidence package rather than any single favourable comparison. The forthcoming natural history poster could help clarify the expected rate and pattern of decline, but its contribution will depend on the quality and relevance of the analyses. More detailed characterization of untreated disease cannot, by itself, prove that TA-ERT prevents neurodegeneration.
What have six years of tralesinidase alfa treatment revealed about biomarker reduction and clinical outcomes?
TA-ERT is a recombinant enzyme replacement therapy designed to restore NAGLU activity within the central nervous system. The investigational molecule combines recombinant human NAGLU with an insulin-like growth factor 2 peptide intended to facilitate cellular uptake through a receptor-mediated pathway. The treatment is administered directly into the brain’s ventricular fluid spaces through an intracerebroventricular delivery system, an approach intended to address the limitations of delivering large enzyme molecules across the blood-brain barrier.
At the February 2026 WORLDSymposium, Spruce presented integrated findings involving 22 patients who had participated in TA-ERT interventional studies and extension programmes, with follow-up extending to approximately six years. The company reported rapid and sustained normalization of CSF HS-NRE during weekly treatment, together with preservation of selected neurological and functional outcomes relative to natural history comparators. The presentation also described stabilization of cortical grey matter volume and normalization of liver and spleen volumes.
The long-term findings provide a potentially important combination of biochemical and functional evidence. They suggest that the treatment may affect the underlying storage disorder while offering signals of preserved capabilities that would otherwise be expected to deteriorate in severe MPS IIIB. Nevertheless, the findings arise from a small treatment population and comparisons with untreated patients who were not assigned through randomized allocation.
Spruce reported that approximately 6,000 doses had been administered across the treated population during the six-year observation period. The company characterized the safety findings as generally consistent with the known considerations associated with intracerebroventricular administration. The cumulative dose experience provides information about repeated exposure, but it should not be interpreted as equivalent to observing thousands of independent patients.
Long-term intracerebroventricular treatment introduces practical and clinical considerations that differ from conventional oral or intravenous medicines. Implanted access devices, repeated procedures, infection prevention, device-related complications and continuing specialist care are relevant to the treatment’s overall benefit-risk assessment. A larger patient population and ongoing surveillance would be important for identifying less common safety events if TA-ERT eventually reaches commercial use.
The available results support continued investigation of the therapy’s potential to alter disease progression, but disease modification remains a clinical conclusion that regulators must evaluate against the complete evidence. The difference between biochemical normalization and sustained neurological benefit will remain central to that assessment.
Why will Spruce’s TrAnsform confirmatory trial be crucial for demonstrating meaningful cognitive benefit?
Spruce’s planned TrAnsform study represents an important next stage because it is intended to evaluate TA-ERT against a concurrent standard-of-care control group. Registered as NCT07579910, the Phase 3 programme is designed as a randomized, single-blind, parallel-group, multicentre investigation involving children between one and five years of age with severe, non-attenuated MPS IIIB. The company expects to enroll approximately 14 participants, reflecting the substantial recruitment challenges associated with the disorder.
The study’s primary objective is to assess the treatment’s effect on cognition, moving beyond the biochemical endpoint central to the planned accelerated approval application. Randomization may help reduce the influence of baseline differences that complicate historical comparisons, although the small population will still present statistical and clinical interpretation challenges. The single-blind design also means that measures potentially influenced by observer or caregiver expectations will require careful evaluation.
The age range is scientifically relevant because the opportunity to preserve developmental abilities may be greater before severe neurological deterioration has occurred. Previous natural history findings indicate that many children experience their highest measured cognitive and adaptive functioning during early childhood before progressive decline becomes more evident. Initiating treatment during this period could provide an opportunity to investigate whether TA-ERT influences the subsequent developmental trajectory.
The FDA has requested that Spruce initiate the confirmatory study while the company’s planned biologics license application is under review as part of the proposed accelerated approval strategy. Spruce expects the programme to begin during the fourth quarter of 2026, while the clinical trial registration identifies December 2026 as its estimated start period. These are planned milestones rather than confirmation that recruitment or dosing has already begun.
The confirmatory programme’s ultimate importance lies in determining whether the biochemical changes observed in earlier studies translate into meaningful preservation of neurological function. A favourable biomarker response may support the proposed accelerated approval application, but the separate clinical study is intended to verify the anticipated benefit. Its results will be relevant to the treatment’s longer-term regulatory position and the confidence of clinicians considering its use.
How does the FDA’s 2026 Hunter syndrome approval affect the regulatory context for TA-ERT?
A relevant regulatory development occurred in March 2026 when the FDA granted accelerated approval to Denali Therapeutics’ Avlayah, containing tividenofusp alfa-eknm, for the neurological manifestations of Hunter syndrome, also known as mucopolysaccharidosis type II. The authorization applies to a defined pediatric population weighing at least five kilograms and treated before advanced neurological impairment. It was based on reduction of cerebrospinal fluid heparan sulfate as a surrogate endpoint reasonably likely to predict clinical benefit.
The decision is important because it demonstrates that the FDA has accepted reduction of a disease-related cerebrospinal fluid heparan sulfate biomarker in a particular neuronopathic lysosomal storage disorder. Spruce has referred to this development while explaining its own regulatory strategy for TA-ERT. However, Hunter syndrome and Sanfilippo syndrome type B are distinct diseases caused by different enzyme deficiencies, and their approved or investigational therapies use different delivery technologies.
Avlayah is administered through intravenous infusion, while TA-ERT requires intracerebroventricular administration. Their clinical evidence packages, target populations, safety considerations and disease mechanisms must therefore be assessed separately. Approval of one enzyme replacement therapy does not establish that another candidate will satisfy the FDA’s requirements or that an equivalent biomarker response will produce the same clinical outcome.
The broader regulatory implication is that biomarker-based accelerated approval can provide a development pathway for serious rare neurological diseases when clinical benefit may require prolonged observation. For Spruce, the relevant question is whether its combined biomarker, longitudinal clinical and natural history evidence supports the proposed indication and regulatory standard. The forthcoming Child Neurology Society presentation may add clinical context to that assessment without removing the need for independent FDA review.
What progress has Spruce made on manufacturing readiness and its fourth-quarter FDA application?
Spruce completed two pre-biologics license application meetings with the FDA during 2026 and reported further regulatory alignment in August. The company said the agency considered its analytical comparability strategies reasonable to support the application following transfer of drug substance and drug product manufacturing to a commercial-scale biologics manufacturer. It also reported agreement on the overall content and organization of the planned application, including integrated efficacy and safety summaries.
These discussions reduce some uncertainty surrounding application preparation but do not constitute advance approval of the product or a guarantee that the eventual submission will be accepted for review. The manufacturing programme remains particularly important because enzyme replacement therapies require consistent biological activity, product quality and validated production processes. Changes associated with transferring manufacturing operations must be supported by evidence that the resulting material remains appropriately comparable.
Spruce reported completing the first process performance qualification batch in July 2026 and planned to finish manufacturing the second batch during the fourth quarter. Its agreed approach contemplated including data from the first qualification batch in the submission and supplying second-batch information before the midpoint of the anticipated application review. This sequencing reflects the company’s attempt to coordinate manufacturing validation with its proposed regulatory timetable.
The company continues to target a fourth-quarter 2026 submission, but an application filing would begin rather than conclude the formal regulatory review process. The FDA would still need to determine whether the submission is sufficiently complete for review and evaluate the clinical, nonclinical and manufacturing evidence. Any eventual accelerated approval would also carry requirements concerning verification of clinical benefit and other applicable post-approval obligations.
Commercial preparedness presents another challenge because TA-ERT would require specialized administration and ongoing treatment infrastructure. Potential availability would depend on regulatory authorization, manufacturing supply, treatment-centre readiness, clinical training and reimbursement arrangements. The company has discussed the possibility of a United States commercial launch in 2027 if approval is obtained, but that remains contingent rather than confirmed.
How do Spruce Biosciences’ finances and stock performance reflect its regulatory-stage risks?
Spruce reported cash and cash equivalents of $96.3 million as of June 30, 2026, compared with $48.9 million at the end of December 2025. Management stated that these resources were expected to fund planned operations and debt obligations into the second half of 2027. The position provides financial capacity for near-term regulatory and clinical activities, although a commercial launch and longer-term confirmatory trial would introduce additional operating requirements.
Research and development expenses reached $12.2 million during the second quarter of 2026, reflecting increased investment in TA-ERT manufacturing and clinical development. The company reported a quarterly net loss of $16.2 million and a six-month net loss of $28.5 million. These figures show the financial demands of moving an investigational biologic toward regulatory review while establishing the operational infrastructure needed for potential commercialization.
Patient advocacy organizations have also provided direct financial support. In August 2026, Cure Sanfilippo Foundation and the National MPS Society made a combined $5.5 million strategic investment in Spruce to help fund an expanded access programme for TA-ERT. The planned programme is intended to provide investigational treatment to approximately 10 children who are not eligible for the TrAnsform confirmatory study, including patients with severe or attenuated disease.
Expanded access can address important treatment needs for patients who cannot participate in conventional trials, but it is not equivalent to regulatory approval or a substitute for controlled efficacy evidence. The programme also involves clinical oversight, product supply and operational costs that need to be considered alongside the company’s remaining development responsibilities. Spruce expects the initiative to begin during the fourth quarter of 2026, subject to the necessary arrangements.
Spruce shares closed at $44.05 on October 9, 2026, declining 3.27% during the session following the company’s announcement. The stock had fallen approximately 21% over the preceding month and was trading substantially below its 52-week high. Its market capitalization stood at approximately $126 million, reflecting a valuation highly sensitive to the perceived probability, timing and commercial implications of TA-ERT’s regulatory progress.
The price movement should not be attributed solely to the natural history presentation announcement because the company disclosed no new efficacy results on October 8. The more consequential catalysts remain the planned biologics license application submission, initiation of the confirmatory study and subsequent FDA decisions. Investors will also need to consider the company’s cash requirements if clinical development or regulatory review extends beyond management’s current timetable.
What should clinicians and investors expect from the October 15 MPS IIIB presentation?
The Child Neurology Society presentation will be particularly relevant if it provides more detailed information about the relationship between cognition, communication, motor abilities and adaptive functioning in untreated children with severe MPS IIIB. These domains capture different aspects of progressive neurological impairment, and understanding how they change over time could improve the design and interpretation of future treatment studies. The presentation may also help determine whether particular assessments remain informative across different ages and stages of disease.
Professor Ilyas Okur is scheduled to present poster 235 during the Neurodevelopmental Disorders session on October 15, 2026. The session will take place during the Child Neurology Society’s annual meeting in Montreal, which runs from October 14 to 17. Spruce has said that the poster will become publicly available following its presentation, allowing the reported methods and findings to be examined in more detail.
The most important scientific considerations will include the number of participants analysed, the duration of follow-up, the severity of disease at baseline and the methods used to measure changes in neurological function. Investigators may also need to explain how they addressed missing observations, differences in disease progression and the limitations of developmental assessments in children with severe impairment. These factors will influence how useful the data are as contextual evidence for TA-ERT development.
For clinicians and families, understanding untreated disease progression has significance beyond an individual regulatory application. Better characterization of the expected neurological course can inform research priorities, clinical assessment and discussions about the development of investigational treatments. However, the natural history study itself does not test a treatment or establish whether a particular intervention can change the course of MPS IIIB.
For Spruce Biosciences, the October presentation arrives at a critical point in the development of tralesinidase alfa. The company has reported long-term biomarker reductions and encouraging functional observations, established a proposed accelerated approval strategy and advanced manufacturing and confirmatory trial preparations. Its next challenge is to assemble these different evidence components into a regulatory package capable of supporting a favourable benefit-risk assessment.
The forthcoming natural history findings could strengthen the interpretation of cognitive and functional outcomes, but they cannot substitute for direct evidence that TA-ERT provides meaningful clinical benefit. The fourth-quarter filing target and planned TrAnsform initiation will therefore be more consequential than the conference announcement alone. Whether Spruce can ultimately establish tralesinidase alfa as a treatment for Sanfilippo syndrome type B will depend on the FDA’s assessment of the complete evidence package and the clinical benefit demonstrated through continued research.
